CBD 101 - What is CBD?
Learn more about the science and efficacy behind CBD
Cibadol believes that education is always important especially when it comes to anything you’re putting in your body.
We proudly share all the basics of CBD and the compelling science behind it.
What Is CBD?
CBD, short for cannabidiol, is a naturally-occurring cannabinoid that’s found within cannabis plants. As one of over hundreds of complex compounds that make up the composition of hemp plants, CBD is nonpsychoactive and offers comprehensive medicinal potential.
How Was CBD Discovered?
CBD was actually first discovered in 1940 by Dr. Roger Adams during his time at the University of Illinois. Although Dr. Adams was the first scientist to successfully extract CBD from the cannabis plant, he wasn’t aware of this accomplishment for several years. Dr. Walter S. Lowe began initial research on the effects of CBD on animals in 1946. This research concluded that CBD had no mind-altering effects, unlike its more popularly known cousin THC.
Mechoulam’s Significant CBD Research
Israeli scientist Raphael Mechoulam made noteworthy strides in CBD research that has revolutionized our understanding of cannabis as well as our own anatomy. During his research, Mechoulam successfully isolated and identified THC. This achievement led to the identification of CBD’s three-dimensional structure. Even though CBD was discovered more than 20 years prior to THC, THC has always dominated cannabis research until recent years. Mechoulam’s significant cannabis research also led to the discovery of the endocannabinoid system.
The Continued Research of CBD
Due to the popular recreational use of cannabis in the United Kingdom and other Western countries, cannabis research continued in the mid-1960s to early 1970s. However, THC research dominated all cannabis studies at this time.
CBD gained momentum as it became the focus of cannabinoid research in 1998 when British pharmaceutical company GW Pharmaceuticals gained licensing in order to cultivate cannabis for their clinical trials. Geoffrey Guy, the co-founder of GW Pharmaceuticals, decided to test his theory that cannabis with high CBD content could provide a significant medical application in creating a cannabis-derived pharmaceutical with no mind-altering effects. Guy hypothesized that the CBD compound had therapeutic value and could potentially counteract the psychoactivity of THC.
The Beginning of the Hemp-Derived CBD Movement
As preclinical research on CBD started emerging in the early 2000s, marijuana still remained federally illegal. This drove a shift towards researching and producing hemp-derived products. While marijuana and hemp are both members of the cannabis family, they differ in appearance, composition, cultivation needs, legality, and phytochemical application. Hemp inherently has a high CBD to low THC ratio, eliminating any psychoactive properties. The 2018 Farm Bill ended hemp prohibition on the federal level, making hemp a legal commodity that can be sold and transported to all 50 states. Whether CBD is derived from marijuana or hemp, it maintains the same chemical makeup and benefit potential. Hemp-derived CBD offers better access to individuals across the nation without the mind-altering effects of marijuana-derived CBD.
The Push for More Clinical CBD Research Today
Due to the popular recreational use of cannabis in the United Kingdom and other Western countries, cannabis research continued in the mid-1960s to early 1970s. However, THC research dominated all cannabis studies at this time.
CBD gained momentum as it became the focus of cannabinoid research in 1998 when British pharmaceutical company GW Pharmaceuticals gained licensing in order to cultivate cannabis for their clinical trials. Geoffrey Guy, the co-founder of GW Pharmaceuticals, decided to test his theory that cannabis with high CBD content could provide a significant medical application in creating a cannabis-derived pharmaceutical with no mind-altering effects. Guy hypothesized that the CBD compound had therapeutic value and could potentially counteract the psychoactivity of THC.
CBD gained momentum as it became the focus of cannabinoid research in 1998 when British pharmaceutical company GW Pharmaceuticals gained licensing in order to cultivate cannabis for their clinical trials. Geoffrey Guy, the co-founder of GW Pharmaceuticals, decided to test his theory that cannabis with high CBD content could provide a significant medical application in creating a cannabis-derived pharmaceutical with no mind-altering effects. Guy hypothesized that the CBD compound had therapeutic value and could potentially counteract the psychoactivity of THC.
CBD Basics
A: No, CBD is a nonpsychoactive compound. Hemp-derived CBD products contain minimal THC content to no THC content which won’t result in any mind-altering effects. Cibadol offers both full-spectrum and CBD isolate options that are all independent, third-party lab tested to ensure proper cannabinoid content.
A: Full-spectrum CBD is meant to mimic the whole plant material of hemp, meaning it will contain 0.3% THC as well as all the other existing cannabinoid and terpene content. Full-spectrum products may be ideal for certain conditions due to the hypothesized entourage effect. Broad-spectrum CBD is also meant to mimic the whole plant material of hemp but with the THC removed. Broad-spectrum offers similar benefits as full-spectrum but with no risk of ingesting THC. CBD isolate refers to 99+% pure CBD with no other cannabinoid or terpene content.
A: CBD has no adverse, long-term side effects and is generally well-tolerated. However, there are many factors that can cause potential side effects including changes in appetite, dry mouth, diarrhea, and fatigue. Here are some things to consider:
Incompatible CBD product: While full-spectrum products are generally believed to be ideal due to the synergetic effort between all cannabinoids, some individuals who are prone to plant allergies may react to the other plant material found in these products. Individuals with plant allergies may be better suited with a CBD isolate product. While self-experimentation and research are key, the Cibadol team is always available to help you find the right product.
Drug interactions: CBD poses potential drug interactions that can account for some of the side effects experienced. Always speak to your healthcare professional before trying CBD.
Dosage and frequency: Dosage and frequency vary from individual to individual, making self-experimentation essential. Too large of a dose or taking CBD too frequently may result in undesirable side effects. However, CBD remains safe in large doses and doesn’t pose any risk for overdose or dependency.
Poor product formulation: The CBD industry is unregulated right now meaning you can potentially purchase harmful or ineffective CBD products. Always purchase CO2-extracted CBD that’s sourced from domestic, non-GMO hemp crops that are either certified organic or grown with strict organic farming practices. This minimizes your risk of being exposed to pesticides or toxic solvents that can cause undesirable side effects. Make sure to always check COAs as well.
A: Yes, similar to grapefruit, St. John’s Wort, and watercress, CBD temporarily deactivates the cytochrome p450 system which is responsible for metabolizing the majority of pharmaceuticals and supplements. We always recommend speaking to your healthcare professional before trying CBD.
A: Yes, hemp-derived CBD with 0.3% THC or less is federally legal. Cibadol facilitates strict testing standards and proudly ships to all 50 states.
Invest In Your Health Today
Cibadol is happy to answer any questions you have regarding our vertical integration. We welcome you to visit us! Start investing in your health today!